Bionomics (Bionomics) Short-Term Debt : $0.75 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bionomics Short-Term Debt?

Bionomics's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.75 Mil.

Bionomics's quarterly Short-Term Debt stayed the same from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.75 Mil).

Bionomics Short-Term Debt Historical Data

The historical data trend for Bionomics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Short-Term Debt Chart

Bionomics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

5.87

3.58

Bionomics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	0.75

Bionomics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bionomics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Bionomics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionomics (Bionomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

B1N0:Germany

Address

200 Greenhill Road, Eastwood, SA, AUS, 5063

Website

https://www.bionomics.com.au

Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.